NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-FD-17-012 from the NIH Guide for Grants and Contracts
Notice NOT-MH-17-044 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-17-503 from the NIH Guide for Grants and Contracts. The NIDDK, in collaboration with the NHLBI and NICHD, invites Cooperative Agreement applications for a limited competition from the Data Coordinating Center (DCC) for The Chronic Kidney Disease in Children (CKiD) consortium. The DCC will work cooperatively with the existing Clinical Coordinating Centers (CCCs) and Central Biochemistry Laboratory (CBL) of the study as a Consortium. Participant evaluations in some domains will be expanded, and follow-up will extend beyond the onset of End Stage Renal Disease (ESRD).
Funding Opportunity RFA-DK-17-502 from the NIH Guide for Grants and Contracts. The NIDDK, in collaboration with the NHLBI and NICHD, invites Cooperative Agreement applications for a limited competition from the two Clinical Coordinating Centers (CCCs) already involved in The Chronic Kidney Disease in Children (CKiD) consortium. The Clinical Centers will continue to evaluate enrolled participants, recruit new participants, and continue to work together cooperatively with the existing Data Coordinating Center (DCC) and Central Biochemistry Laboratory (CBL) of the study as a Consortium. Participant evaluations in some domains will be expanded, and follow-up will extend beyond the onset of End Stage Renal Disease (ESRD).
Funding Opportunity RFA-DK-17-034 from the NIH Guide for Grants and Contracts. The NIDDK invites Cooperative Agreement applications for an open competition for the Central Biochemistry Laboratory (CBL) of The Chronic Kidney Disease in Children (CKiD) consortium. The CBL will work cooperatively with the existing Clinical Coordinating Centers (CCCs) and Data Coordinating Center (DCC) of the study as a Consortium. Participant evaluations in some domains will be expanded, and follow-up will extend beyond the onset of End Stage Renal Disease (ESRD).
Notice NOT-DK-17-017 from the NIH Guide for Grants and Contracts
Notice NOT-RM-17-037 from the NIH Guide for Grants and Contracts
Notice NOT-DK-17-016 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-17-461 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to encourage preclinical and clinical research and secondary data analysis on symptom cluster characterization that has potential to inform treatment and interventions that improve functional outcomes and quality of life in patients with chronic conditions.
Funding Opportunity PA-17-462 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to encourage preclinical and clinical research and secondary data analysis on symptom cluster characterization that has potential to inform treatment and interventions that improve functional outcomes and quality of life in patients with chronic conditions.
Funding Opportunity PA-17-460 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies.
Notice NOT-OD-17-103 from the NIH Guide for Grants and Contracts
Notice NOT-HD-17-023 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-17-015 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide the Metabolomics Core for Phase II of the Undiagnosed Diseases Network (UDN).
Funding Opportunity RFA-RM-17-016 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide support for sequencing for Phase II of the Undiagnosed Diseases Network (UDN).
Funding Opportunity RFA-RM-17-017 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide a Model Organisms Screening Center for Phase II of the Undiagnosed Diseases Network (UDN). The Center will evaluate the pathogenicity and function of approximately 200 gene variants per year identified through the UDN. Responsive applications will propose to establish a screening strategy for selecting the most informative variants for analysis, and a research platform involving at a minimum Drosophila and zebrafish models. The screening pipeline may include additional small animal models or cell-based assays, as appropriate, to analyze the function of UDN gene variants in the context of the respective UDN participants disease phenotype. This initiative is funded through the NIH Common Fund which supports cross-cutting programs that are expected to have exceptionally high impact.
Funding Opportunity RFA-RM-17-018 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide a Coordinating Center for Phase II of the Undiagnosed Diseases Network (UDN).
Funding Opportunity RFA-RM-17-019 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide Clinical Sites for Phase II of the Undiagnosed Diseases Network (UDN).
Notice NOT-HD-17-022 from the NIH Guide for Grants and Contracts
Notice NOT-EY-17-009 from the NIH Guide for Grants and Contracts